Literature DB >> 36099321

Clinical usefulness of the pattern of non-adherence to anti-platelet regimen in stented patients (PARIS) thrombotic risk score to predict long-term all-cause mortality and heart failure hospitalization after percutaneous coronary intervention.

Joh Akama1, Takeshi Shimizu1, Takuya Ando1, Fumiya Anzai1, Yuuki Muto1, Yusuke Kimishima1, Takatoyo Kiko1, Akiomi Yoshihisa1, Takayoshi Yamaki1, Hiroyuki Kunii1, Kazuhiko Nakazato1, Takafumi Ishida1, Yasuchika Takeishi1.   

Abstract

BACKGROUND: The Patterns of non-Adherence to Anti-Platelet Regimen in Stented Patients (PARIS) thrombotic risk score has been proposed to estimate the risk of stent thrombotic events after percutaneous coronary intervention (PCI). However, the prognostic value of the PARIS thrombotic risk score for long term all-cause and cardiac mortalities, as well as hospitalization due to heart failure, has not yet been evaluated. Therefore, the aim of the present study was to evaluate the prognostic value of the PARIS thrombotic risk score for all-cause and cardiac mortalities and hospitalization due to heart failure following PCI. METHODS AND
RESULTS: Consecutive 1,061 patients who underwent PCI were divided into three groups based on PARIS thrombotic risk score; low- (n = 320), intermediate- (n = 469) and high-risk (n = 272) groups. We followed up on all three groups for all-cause mortality, cardiac mortality and hospitalization due to heart failure. Kaplan-Meier analysis showed that all outcomes were highest in the high-risk group (P < 0.001, P = 0.022 and P < 0.001, respectively). Multivariate Cox proportional hazard analysis, adjusted for confounding factors, showed that the risk of all-cause mortality and hospitalization due to heart failure of the high-risk group were higher than those of the low-risk group (hazard ratios 1.76 and 2.14, P = 0.005 and P = 0.017, respectively).
CONCLUSION: The PARIS thrombotic risk score is a significant prognostic indicator for all-cause mortality and hospitalization due to heart failure in patients after PCI.

Entities:  

Mesh:

Year:  2022        PMID: 36099321      PMCID: PMC9469967          DOI: 10.1371/journal.pone.0274287

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.752


  25 in total

1.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Authors:  Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal:  BMJ       Date:  2007-10-20

2.  ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.

Authors:  Ph Gabriel Steg; Stefan K James; Dan Atar; Luigi P Badano; Carina Blömstrom-Lundqvist; Michael A Borger; Carlo Di Mario; Kenneth Dickstein; Gregory Ducrocq; Francisco Fernandez-Aviles; Anthony H Gershlick; Pantaleo Giannuzzi; Sigrun Halvorsen; Kurt Huber; Peter Juni; Adnan Kastrati; Juhani Knuuti; Mattie J Lenzen; Kenneth W Mahaffey; Marco Valgimigli; Arnoud van 't Hof; Petr Widimsky; Doron Zahger
Journal:  Eur Heart J       Date:  2012-08-24       Impact factor: 29.983

3.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2016-05-20       Impact factor: 15.534

4.  Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score.

Authors:  Amir Halkin; Mandeep Singh; Eugenia Nikolsky; Cindy L Grines; James E Tcheng; Eulogio Garcia; David A Cox; Mark Turco; Thomas D Stuckey; Yingo Na; Alexandra J Lansky; Bernard J Gersh; William W O'Neill; Roxana Mehran; Gregg W Stone
Journal:  J Am Coll Cardiol       Date:  2005-05-03       Impact factor: 24.094

5.  ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina).

Authors:  E Braunwald; E M Antman; J W Beasley; R M Califf; M D Cheitlin; J S Hochman; R H Jones; D Kereiakes; J Kupersmith; T N Levin; C J Pepine; J W Schaeffer; E E Smith; D E Steward; P Theroux; J S Alpert; K A Eagle; D P Faxon; V Fuster; T J Gardner; G Gregoratos; R O Russell; S C Smith
Journal:  J Am Coll Cardiol       Date:  2000-09       Impact factor: 24.094

6.  Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction.

Authors:  Erin A Bohula; Marc P Bonaca; Eugene Braunwald; Philip E Aylward; Ramon Corbalan; Gaetano M De Ferrari; Ping He; Basil S Lewis; Piera A Merlini; Sabina A Murphy; Marc S Sabatine; Benjamin M Scirica; David A Morrow
Journal:  Circulation       Date:  2016-07-26       Impact factor: 29.690

7.  Investigation of the freely available easy-to-use software 'EZR' for medical statistics.

Authors:  Y Kanda
Journal:  Bone Marrow Transplant       Date:  2012-12-03       Impact factor: 5.483

8.  Predictors of hospital mortality in the global registry of acute coronary events.

Authors:  Christopher B Granger; Robert J Goldberg; Omar Dabbous; Karen S Pieper; Kim A Eagle; Christopher P Cannon; Frans Van De Werf; Alvaro Avezum; Shaun G Goodman; Marcus D Flather; Keith A A Fox
Journal:  Arch Intern Med       Date:  2003-10-27

9.  Prognostic Value of the PARIS Thrombotic Risk Score for 2-Year Mortality After Percutaneous Coronary Intervention.

Authors:  Xueyan Zhao; Jianxin Li; Xiaofang Tang; Ying Xian; Lin Jiang; Jue Chen; Lijian Gao; Zhan Gao; Shubin Qiao; Yuejin Yang; Runlin Gao; Bo Xu; Jinqing Yuan
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

10.  The clinical value of the PRECISE-DAPT score in predicting long-term prognosis in patients with acute myocardial infarction.

Authors:  Takuya Ando; Kazuhiko Nakazato; Yusuke Kimishima; Takatoyo Kiko; Takeshi Shimizu; Tomofumi Misaka; Shinya Yamada; Takashi Kaneshiro; Akiomi Yoshihisa; Takayoshi Yamaki; Hiroyuki Kunii; Yasuchika Takeishi
Journal:  Int J Cardiol Heart Vasc       Date:  2020-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.